# Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

> **NCT02097238** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Osteosarcoma

## Interventions

- **DRUG:** Eribulin Mesylate
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02097238
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-06-30
- **Final completion:** 2020-03-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02097238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02097238, "Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02097238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*